Elsevier

Molecular and Cellular Endocrinology

Volume 413, 15 September 2015, Pages 202-208
Molecular and Cellular Endocrinology

YC-1 reduces placental sFlt-1 and soluble endoglin production and decreases endothelial dysfunction: A possible therapeutic for preeclampsia

https://doi.org/10.1016/j.mce.2015.06.033Get rights and content

Highlights

  • Preeclampsia is a serious complication affecting 5–8% of pregnancies.

  • YC-1 reduces sFlt-1 and sENG secretion from primary human tissues.

  • It inhibits HIF1α expression in placenta.

  • YC-1 reduces endothelial dysfunction.

  • YC-1 is a novel potential therapeutic for preeclampsia.

Abstract

Preeclampsia is a serious complication of pregnancy with no medical treatment. It is caused by intermittent placental hypoxia and release of sFlt-1 and soluble endoglin, leading to wide spread maternal endothelial dysfunction and multisystem organ injury. YC-1 is a guanylyl cyclase activator and HIF1α inhibitor developed for use in hypertension and atherosclerosis. We examined whether YC-1 reduces sFlt-1 and sENG secretion and reverses endothelial dysfunction in primary human tissues. YC-1 significantly reduced sFlt-1 and sENG secretion from human umbilical vein endothelial cells, purified primary trophoblast cells and placental explants taken from patients with preterm preeclampsia. This was concordant with reduced HIF1α expression. YC-1 also reversed TNFα induced endothelial dysfunction, including reduced vascular cell adhesion molecule 1 expression and monocyte adhesion to primary endothelial cells. We conclude YC-1 decreases placental production of sFlt-1 and sENG and decreases endothelial dysfunction. It is a novel therapeutic candidate for preeclampsia.

Introduction

Preeclampsia is a leading cause of maternal and perinatal mortality and morbidity (Redman and Sargent, 2005, Sibai et al., 2005). A crucial step in the pathogenesis is the release of anti angiogenic factors sFlt-1 (Maynard et al., 2003) and soluble endoglin (Venkatesha et al., 2006) into the maternal vasculature. This leads to widespread endothelial dysfunction and multisystem organ injury and failure. Currently there is no medical treatment and delivery at preterm gestations is often required to stop disease progression (Chaiworapongsa et al., 2014a). A medical therapeutic that stabilizes the disease process and allows pregnancies to safely continue, could significantly improve fetal and maternal outcomes (Chaiworapongsa et al., 2014b).

The etiology of preeclampsia is believed to stem from abnormal placental trophoblast invasion into maternal uterine spiral arteriols (Redman and Sargent, 2005, Sibai et al., 2003). This is thought to result in inadequate placental perfusion and hypoxia and leads to increased secretion of sFlt-1 and soluble endoglin (sENG) (Redman and Sargent, 2005, Karumanchi and Bdolah, 2004). This premise is supported by the clinical observation that patients with preeclampsia have a 50–70% reduction in uteroplacental blood flow (Lunell et al., 1984). Furthermore, restricting uterine blood flow in pregnant rats increases serum sFlt-1 and induces a preeclamptic-like phenotype (Granger et al., 2006). Hypoxic-inducible factor-1α (HIF1α) is the master regulator of the hypoxic response and has been found to be increased in preeclampsia (Caniggia and Winter, 2002, Rajakumar et al., 2004). Over-expression of HIF1α in pregnant mice recapitulates the preeclamptic phenotype including elevated circulating sFlt-1, hypertension and proteinuria (Tal et al., 2010). Therefore, a medication that blocks HIF1α could represent a therapeutic strategy for preeclampsia, as it may decrease placental production of sFlt-1 and sENG (Rana et al., 2014).

Endothelial dysfunction is responsible for the maternal preeclampsia phenotype and results in widespread end organ injury (Borzychowski et al., 2006). It is likely caused by an increase in circulating antiangiogenic factors sFlt-1 and sENG and an elevation in the potent vasoconstrictor endothelin 1 (Nishikawa et al., 2000) and pro-inflammatory cytokine TNFα (Sanchez-Aranguren et al., 2014). Thus, a drug that can reduce endothelial dysfunction may also be useful as a treatment for preeclampsia.

YC1 3-(5′-hydroxymethyl-2′-furyl)-1-benzylindazole is a cardiovascular medication (Stasch et al., 2011) that quenches endothelial dysfunction (Galle et al., 1999) by inducing nitric oxide (Wohlfart et al., 1999), a potent vasodilator, and also independently activates its receptor guanylyl cyclase (Ramos-Espiritu et al., 2011). It has also been found to inhibit HIF1α (Yeo et al., 2003). Given its known vasoprotective properties and its ability to block HIF1α we hypothesize that YC-1 may reduce sFlt-1 and sENG secretion from primary human pregnancy tissues and rescue the endothelial dysfunction characteristic of preeclampsia. We therefore undertook functional studies in primary human tissues to examine the potential of YC-1 as a novel treatment for preeclampsia.

Section snippets

Placenta explant culture

Human placental tissue was collected from three women with normal pregnancy at term and also three women with severe early onset preeclampsia (delivered at ≤34 weeks gestation). Preeclampsia was defined using the 2013 American College of Obstetricians and Gynecologists (ACOG) guidelines: the presence of hypertension >140/90 on two occasions 4 h apart and any of the following: proteinuria >300 mg/day, renal insufficiency, impaired liver function, thrombocytopenia or visual disturbance (ACOG, 2013

Theory

We hypothesise that YC-1, a HIF1α inhibitor and guanylyl cyclase activator, will reduce sFlt-1 and sENG secretion and improve endothelial dysfunction.

YC1 reduces sFlt-1 secretion from primary human tissues

Firstly we examined the effect of YC-1 on sFlt-1 secretion from primary trophoblasts and from placental explants obtained from women undergoing a term normal pregnancy and from patients diagnosed with preterm preeclampsia. YC-1 dose dependently reduced sFlt-1 secretion from primary trophoblasts (Fig. 1A). There was no change to sFlt-1 secretion from normal placental explants treated with YC-1 when cultured at 8% oxygen (Fig. 1B) however a reduction in secretion occurred when cultured at 1%

Discussion

Preeclampsia is a devastating complication of pregnancy with no medical treatment. A drug that can reduce placental secretion of anti-angiogenic factors sFlt-1 and sENG and rescue endothelial dysfunction may stabilize the disease process and reduce subsequent maternal and perinatal mortality and morbidity. Placental hypoxia and elevation of HIF1α is an upstream event in the pathogenesis of preeclampsia (Karumanchi and Bdolah, 2004) that leads to increased secretion of sFlt-1 and sENG and

Conclusion

The data presented suggest that the effects of YC-1 on sFlt1 and sENG involve modulation of HIF1α expression. Importantly other mechanisms may also contribute to the mode of action of YC-1. Elucidation of other pathways downstream of YC-1, as well as other inhibitors of HIF1α, may lead to additional approaches for preeclampsia therapy.

Sources of funding

This work was funded by The National Health and Medical Research Council of Australia (NHMRC; #1048707, #1046484) and an Arthur Wilson RANZCOG scholarship. FB was supported by an Australian Postgraduate Award and an AVANT scholarship. The NHMRC provided salary support (#1050765 to ST #1062418 to TKL, #628927 to NJH). The funders had no role in study design, data collection, analysis, decision to publish or helped to prepare the manuscript.

Acknowledgments

We would also like to thank the research midwives, Gabrielle Pell, Genevieve Christophers, Rachel Murdoch and Debra Jinks, and patients at Mercy Hospital for Women for participating in this research.

References (32)

  • T. Chaiworapongsa et al.

    Pre-eclampsia part 1: current understanding of its pathophysiology

    Nat. Rev. Nephrol.

    (2014)
  • T. Chaiworapongsa et al.

    Pre-eclampsia part 2: prediction, prevention and management

    Nat. Rev. Nephrol.

    (2014)
  • J. Galle et al.

    Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity

    Br. J. Pharmacol.

    (1999)
  • J.P. Granger et al.

    Reduced uterine perfusion pressure (RUPP) model for studying cardiovascular-renal dysfunction in response to placental ischemia

    Methods Mol. Med.

    (2006)
  • J. Jebbink et al.

    Expression of placental FLT1 transcript variants relates to both gestational hypertensive disease and fetal growth

    Hypertension

    (2011)
  • S.A. Karumanchi et al.

    Hypoxia and sFlt-1 in preeclampsia: the “chicken-and-egg” question

    Endocrinology

    (2004)
  • Cited by (28)

    • Pravastatin, proton-pump inhibitors, metformin, micronutrients, and biologics: new horizons for the prevention or treatment of preeclampsia

      2022, American Journal of Obstetrics and Gynecology
      Citation Excerpt :

      For instance, we36 and others72 have demonstrated that direct inhibition of the 3-hydroxy-methylglutaryl coenzyme A reductase pathway (the direct target of statins) can decrease sFlt-1 secretion. Furthermore, inhibiting the hypoxia-inducible factor-1 alpha (HIF-1α) pathway also reduces sFlt-1 secretion.68 Given that proton-pump inhibitors49 and metformin73–75 inhibit HIF-1α expression, this may be another mechanism by which these drugs inhibit sFlt-1 release.

    • Esomeprazole and sulfasalazine in combination additively reduce sFlt-1 secretion and diminish endothelial dysfunction: potential for a combination treatment for preeclampsia

      2020, Pregnancy Hypertension
      Citation Excerpt :

      Thus, lower concentrations of esomeprazole and sulfasalazine in combination do not additively reduce sENG secretion from placental explants or primary HUVECs. Using our well established in vitro models [20,33–37], TNF-α was used to induce endothelial dysfunction in primary HUVECs. Cell viability was not affected by the addition of TNF-α (Supplementary Fig. 1).

    • Hypoxia-induced and HIF1α-VEGF-mediated tight junction dysfunction in choriocarcinoma cells: Implications for preeclampsia

      2019, Clinica Chimica Acta
      Citation Excerpt :

      We speculate that the hypoxia-induced TJ dysfunction in trophoblasts might cause the release of anti-angiogenic factors, such as soluble Fms-like tyrosine kinase-1 (sFLT-1) and soluble endoglin (sENG), into the maternal vasculature, and this is believed to be a crucial step in the pathogenesis of PE [29]. Moreover, YC-1 has been shown to reduce sFLT-1 and sENG secretion from human primary trophoblast cells and placental explants derived from patients with PE, concordant with the downregulation of HIF1α expression [30]. These data emphasize the significance of hypoxia-induced HIFα and the potential role of VEGF in the development of PE.

    • Nanomedicine as a potential approach to empower the new strategies for the treatment of preeclampsia

      2018, Drug Discovery Today
      Citation Excerpt :

      Ouabain inhibited HIF1α in the three models but no inhibition of Flt-1 gene splicing was shown, only an inhibition of transcription of sFlt-1 and Flt-1 [36]. sFlt-1 expression was reduced after exposure to YC-1, a HIF1α-I and a guanylyl cyclase activator [37]. Metformin was able to inhibit HIF1α by reducing mitochondrial electron transport chain activity.

    View all citing articles on Scopus
    View full text